arrow
H

Hans-Peter Brunner-La Rocca

Maastricht University Medical Center
H指数:75
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expert Agreement on Palliative Reasoning and Monitoring in Heart Failure: International Delphi Study

心力衰竭姑息治疗决策与监测的国际专家共识研究

2026-10-050
OA
Bayesian networks to estimate prognosis in vascular cognitive impairment and small vessel disease: Integrated analyses of interdependent contributors to multiple outcomes

贝叶斯网络用于估算血管性认知障碍和小血管疾病的预后:对多重结局的相互依赖性贡献的整合分析

2026-10-020
OAAI
Automated Assessment of Echocardiograms to Aid Diagnosis of Heart Failure with Preserved Ejection Fraction

利用回声心动图自动化评估辅助诊断射血分数保留的心力衰竭

2026-09-040
OAAI
Differences between men and women in guideline-directed medical therapy implementation, tolerability, and outcomes in heart failure with reduced ejection fraction

心衰射血分数降低患者中,男性和女性在指南指导下的药物治疗实施、耐受性和结局方面的差异

2026-07-250
OAAI
Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma Proteomics

螺内酯和心力衰竭风险中的纤维化:HOMAGE试验血浆蛋白质组学的机器学习分析

MedComm
IF10.7
2026-02-170
OAAI
Patient-reported outcome and experience measures in cardiovascular disease: a scoping review as part of iCARE4CVD

心血管疾病中的患者报告结局与体验测量:作为iCARE4CVD一部分的范围综述

2025-12-091
PRE
Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: Effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF

心力衰竭伴射血分数降低的指南推荐药物治疗真实世界实施:对预后和左心室射血分数的影响。TITRATE-HF研究主要结果

2025-08-140
PREAI
High societal costs and reduced health-related quality of life in inflammatory and systemic immune disease-associated dilated cardiomyopathies

社会成本高昂及炎症性和系统性免疫疾病相关扩张型心肌病患者的健康相关生活质量降低

2025-07-300
OA
The diagnostic yield of an elaborate workup for comorbidities in a real-life heart failure with preserved ejection fraction outpatient population

在真实世界中,对射血分数保留的心力衰竭门诊患者进行详细合并症检查的诊断收益

2025-07-012
OAAI
The Association Between Serially Measured Circulating Biomarker Patterns and Pulmonary Artery Pressures Measured by Invasive Hemodynamic Monitoring

连续测量的循环生物标志物模式与通过侵入性血流动力学监测测量的肺动脉压力之间的关联

2025-05-230
OAAI
Cytotoxic T Cells Drive Outcome in Inflammatory Dilated Cardiomyopathy
2024-12-061
PRE
Optimizing heart failure pathways to enhance patient care: the Program to Optimize Heart Failure Patient Pathways (PRO-HF)

优化心力衰竭途径以增强患者护理: 优化心力衰竭患者途径 (pro-hf) 的计划

2024-06-240
OA
Standardized assessment of evidence supporting the adoption of mobile health solutions: A Clinical Consensus Statement of the ESC Regulatory Affairs Committee

支持采用移动医疗解决方案的证据的标准化评估: ESC监管事务委员会的临床共识声明

2024-06-041
OAAI
Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: Design and rationale of the BioMEMS study
2024-06-022
OAAI
Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE-HF study

新的,慢性的和恶化的心力衰竭患者的当代指南指导的药物治疗: 来自TITRATE-HF研究的第一个数据

2024-05-123
OA